cancer

Is Pharmacyclics the Next Celgene?

Pharmacyclics has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica,...

Pharma's Huge Bet on Immunotherapies

Large pharmaceutical companies are pouring billions worth of funding into a new generation of anti-cancer drugs that use a newly discovered...

Verastem Inc.'s Upcoming Catalysts

Verastem is having its annual research and development day in a few weeks, on July 10. Call it a catalyst to announce catalysts. We...

ASCO: Cancer Drug Showdown

While immuno-oncology was certainly hot at this year's American Society of Clinical Oncology meeting, there were plenty of data on other...

Has Melanoma Finally Met Its Match?

The race in immuno-oncology got a little more clarity at ASCO on Monday as both Bristol Myers and Merck presented impressive data in their...